Lupus anticoagulants in systemic lupus erythematosus: prevalence and clinical associations.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 2125409.
- Also identified by PMC identifier 1004293.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The prevalence of lupus anticoagulant (LAC) and its relation with reported clinical associations has been determined in 55 patients with systemic lupus erythematosus (SLE) from northern India who were studied prospectively. Kaolin clotting time was used to screen for LAC, which was detected in seven (13%) of the patients. Significant associations were found between LAC and thrombotic events, onset of disease at an early age, and disease of shorter duration. No statistically significant association could be found between LAC and recurrent abortions, pulmonary hypertension, thrombocytopenia, and neurological manifestations. It is concluded that LAC is a useful marker for a subset of patients with SLE at risk of thromboembolic events.
Medical subject headings
- Autoantibodies
- Blood Coagulation Factors
- Lupus Erythematosus, Systemic